论文部分内容阅读
[目的]探讨序贯疗法在消化性溃疡患者治疗中的临床应用价值及意义。[方法]选取我院2013年6月~2014年6月期间所收治的幽门螺杆菌阳性消化性溃疡患者90例,随机分为研究组和对照组各45例。研究组患者采用序贯疗法,而对照组患者则采用传统三联疗法,并分别对两组患者的临床治疗情况、临床指标变化情况及不良反应发生情况进行比较和分析。[结果]与对照组相比,研究组患者的幽门螺杆菌根治率91.11%和总有效率95.56%均显著提高,经过统计学处理,差异均具有统计学意义(χ2=3.92,6.15;P<0.05);研究组患者治疗后血清中NO(34.60±10.81)μmol/L、IL-10(265.45±45.27)ng/L、IL-17(45.75±9.32)pg/ml水平均显著降低,经过统计学处理,差异均有统计学意义(t=5.63,3.48,5.54;P<0.05);研究组患者头晕头痛、恶心呕吐、腹泻腹痛、皮疹瘙痒等不良反应的总发生率11.11%明显减少,差异有统计学意义(χ2=4.44;P<0.05)。[结论]序贯疗法在提升幽门螺杆菌阳性消化性溃疡患者临床疗效,改善相关临床指标及降低不良反应方面均具有积极的现实意义,适宜临床应用和推广。
[Objective] To investigate the clinical value and significance of sequential therapy in the treatment of patients with peptic ulcer. [Method] Ninety patients with Helicobacter pylori-positive peptic ulcer admitted in our hospital from June 2013 to June 2014 were randomly divided into study group (45 cases) and control group (45 cases). Patients in the study group were treated with sequential therapy, while patients in the control group were treated with traditional triple therapy. Clinical treatment, clinical changes and adverse reactions were compared and analyzed between the two groups. [Result] Compared with the control group, the cure rate of Helicobacter pylori in study group was 91.11% and the total effective rate was 95.56%, and the difference was statistically significant (χ2 = 3.92,6.15; P < 0.05). The levels of NO (34.60 ± 10.81) μmol / L, IL-10 (265.45 ± 45.27) ng / L and IL-17 (45.75 ± 9.32) pg / ml in the study group were significantly decreased after treatment (T = 5.63,3.48,5.54; P <0.05). The total incidence of dizziness, headache, nausea and vomiting, abdominal pain and pruritus in the study group was significantly decreased There was statistical significance (χ2 = 4.44; P <0.05). [Conclusion] Sequential therapy has the positive and practical significance in improving the clinical efficacy, improving the related clinical indexes and reducing the adverse reactions in Helicobacter pylori positive peptic ulcer patients, and is suitable for clinical application and promotion.